Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies

Jennifer Vogel, Liyong Lin, Charles B. Simone, Abigail T. Berman

Research output: Contribution to journalArticlepeer-review

Abstract

Background: While often managed with surgery alone, patients with thymic malignancies with high-risk features may benefit from adjuvant radiation therapy but are at risk for late toxicities. Previously, the risk of major cardiac events (MCEs) was reported to increase by 7% per one Gray (Gy) to the heart. In this study, we compare dose to organs at risk (OARs) with intensity-modulated (IMRT) versus proton beam therapy (PBT). We hypothesize a decrease risk of predicted MCEs with PBT. Material and methods: Patients requiring adjuvant therapy for thymic malignancies were treated with double scattered proton beam therapy (DS-PBT). Clinical backup IMRT plans were generated. Predicted MCEs were calculated based on median dose to the heart. A Wilcoxon rank sum test was used for statistical comparisons. Results: Twenty-two consecutive patients were evaluated. DS-PBT resulted in statistically significant decreases in dose to the heart, lungs, left ventricle, esophagus, and spinal cord (all p ≤.01). The increase in risk of MCEs from 0 to ≥20 years was lower with PBT (74% versus 135%, p =.04). Discussion: DS-PBT results in decreased dose to OARs and may reduce the risk of MCEs compared with IMRT. Long-term follow-up is required to assess for clinical benefit from DS-PBT.

Original languageEnglish (US)
Pages (from-to)1060-1064
Number of pages5
JournalActa Oncologica
Volume56
Issue number8
DOIs
StatePublished - Aug 3 2017
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies'. Together they form a unique fingerprint.

Cite this